TerminatedPhase 3ACTRN12606000085572

Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care

Sponsor

Prince of Wales Hospital

Enrollment

60 participants

Start Date

Mar 1, 2006

Study Type

Interventional

Conditions

Sex: Both males and femalesMin Age: 18 Yearss

Patient requiring invasive ventilation for longer than 24 hours. 2. Receiving narcotics and /or sedatives for longer than 24 hours. 3. Development of clinical agitation and/or delirium upon weaning narcotics and/or sedatives on commencement of weaning from mechanical ventilation as per the POWSS. 4. Informed consent signed by person responsible within 24 hours of enrolment.

Allergy to any of the trial drugs.2. Patients who are or likely to be pregnant or lactating.3. Any patient with a Body Mass Index of >304. Patients receiving other long term alpha 2 agonists.5. Involvement in a sedation study within the last 30 days.6. Known opiate or benzodiazepines dependence, treatment for chronic pain or recent detoxification therapy within the last 6 months. 7. Patients on anti-psychotic drugs 8. Known dementia, Parkinsonism or epilepsy.9. Patients with recent cerebro-vascular surgery or traumatic brain injury.10. Any evidence of critical illness polyneuropathy.11. Patient with a recent tracheostomy.12. Recent surgery involving free flap.13. Haemodynamically unstable patients with Systolic blood pressure < 90 mmHg and or Heart rate < 55 / min.14. Patients on CVVHD.15. Patients with hepatic encephalopathy within 14 days.16. Patients with a recent drug overdose or CO poisoning.17. Patients who are Non-English Speaking background.

Interested in this trial?

Get notified about updates and connect with the research team.

Patients will be randomised to receive IV Haloperidol 5 mg 6 hourly after loading

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

ACTRN12606000085572